A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Ibrutinib (Primary) ; Ixazomib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PrE0404
- 14 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Apr 2018.
- 15 Jan 2018 Status changed from not yet recruiting to recruiting.
- 31 Oct 2017 New trial record